April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Interleukin 17 (IL17) Levels in Diabetic Patients is Associated With Diabetic Macular Edema and Diabetic Retinopathy
Author Affiliations & Notes
  • M. Bartoli
    Ophthalmology, Medical College of Georgia, Augusta, Georgia
  • F. Facchiano
    Hematology Oncology and Molecolar Medicine, Istituto Superiore di Sanità, Rome, Italy
  • L. Di Renzo
    Experimental Medicine and Pathology, Università La Sapienza, Rome, Italy
  • A. Montemari
    Ophthalmology, IRCCS Fondazione G.B. Bietti, Rome, Italy
  • B. Boccassini
    Ophthalmology, IRCCS Fondazione G.B. Bietti, Rome, Italy
  • M. Parravano
    Ophthalmology, IRCCS Fondazione G.B. Bietti, Rome, Italy
  • F. Lamoke
    Ophthalmology, Medical College of Georgia, Augusta, Georgia
  • D. M. Marcus
    Southeastretina, Augusta, Georgia
  • M. Varano
    Ophthalmology, IRCCS Fondazione G.B. Bietti, Rome, Italy
  • Footnotes
    Commercial Relationships  M. Bartoli, None; F. Facchiano, None; L. Di Renzo, None; A. Montemari, None; B. Boccassini, None; M. Parravano, None; F. Lamoke, None; D.M. Marcus, None; M. Varano, None.
  • Footnotes
    Support  Progetto Finalizzata Italian Ministry of Health, IRCCS Fondazione G. B. Bietti
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5625. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Bartoli, F. Facchiano, L. Di Renzo, A. Montemari, B. Boccassini, M. Parravano, F. Lamoke, D. M. Marcus, M. Varano; Interleukin 17 (IL17) Levels in Diabetic Patients is Associated With Diabetic Macular Edema and Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5625.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Chronic inflammatory processes have been implicated in the pathogenesis of DR. Interleukin 17 (IL-17), a product of Th17 lymphocytes, has been recently shown to play a critical role in sustaining inflammatory processes associated with chronic conditions, such as rheumatoid arthritis and others. In the present study we wanted to investigate whether IL-17 was involved in the pathogenesis of DR.

Methods: : Clinical assessment of DR was conducted by fluorescein angiography following standard protocols. Flow cytometry analysis (FACS) was used to measure the ratio of Th17 lymphocytes within the CD4+ population of circulating immunocytes of diabetic patients (Type 1 = 25 and Type 2= 40) and compared to healthy, age-matched control volunteers (20). Multiplex ELISA was used to measure plasma levels of IL-17 in diabetic patients (Type 1 and Type 2) and in post-mortem vitrei obtained from diabetic donors (Georgia Eye Bank).

Results: : The ratio of Th17 lymphocytes, within the CD4+ immunocytes, was increased in all the diabetic patients and this effect was maximal in patients presenting signs of retinopathy (28%, p<0.03). Plasma circulating levels of IL-17 were also increased in both Type 1 and Type 2 diabetic patients and were significantly elevated in patients presenting signs of retinopathy (p<0.02) and in post-mortem vitrei although levels of IL-17 found in this tissue were more modest of the plasma levels. Finally, correlation studies also revealed that levels of IL-17 correlated with presence of macular edema in both Type 1 and Type 2 diabetic patients.

Conclusions: : The results of the present studies revealed that patients presenting clinical signs of DR, in particular macular edema, have increased levels of Th17 lymphocytes and plasma levels of IL-17. Given the emerging role of IL-17 in sustaining chronic inflammatory diseases, our data suggest a possible implication of this cytokine in the pathogenesis of DR.

Keywords: diabetic retinopathy • diabetes • inflammation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×